Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma

L Zhuang, C S Lee, R A Scolyer, S W McCarthy, A A Palmer, X D Zhang, J F Thompson, L P Bron, P Hersey

Background: Several studies suggest that melanoma may be resistant to treatment because of resistance to apoptosis and that this may be the result of activation of the extracellular signal regulated kinase (ERK1/2) pathway.

Aims: To test this hypothesis by examining the expression of ERK1/2 and its activated form in histological sections of melanoma and its relation to known prognostic features of the disease.

Materials/Methods: Immunohistochemistry with antibodies to ERK1/2 and phosphorylated ERK (p-ERK) was performed on formalin fixed sections from 42 primary melanomas, 38 metastases, and 20 naevi. Fourteen of the primary melanomas were in the radial and 28 in the vertical growth phase.

Results: ERK1/2 was widely expressed (100%) in all the (pigmented) lesions studied. p-ERK1/2 expression was much lower in compound (32.4%) and dysplastic (54.5%) naevi than in primary melanoma (nodular 78.8%, superficial spreading 67%) and subcutaneous metastases (76.3%). p-ERK expression was much lower in lymph node metastases (48.5%), suggesting that the microenvironment may influence the activation of ERK. There was a trend for overall survival to be related to p-ERK expression in patients with melanoma over 1 mm in thickness.

Conclusions: Expression of activated ERK1/2 in melanocytic lesions appears to be related to malignant potential so that activation of ERK1/2 may be important in melanoma progression. These results provide important histological support for the proposal that inhibition of this signalling pathway may be useful in treatment of melanoma.
findings that activation of this pathway is common in melanoma, although a strong relation to existing prognostic factors was not seen.

**MATERIALS AND METHODS**

**Patient material**

The tissue blocks of specimens from 100 patients were retrieved from the archival files of the department of anatomical pathology at Royal Prince Alfred Hospital, Sydney, Australia. These had been surgically excised during the period 2000–3. The cases consisted of (1) 42 primary cutaneous melanomas, including 18 nodular melanomas, 14 superficial spreading melanomas, four desmoplastic melanomas, three in situ melanomas, two acral lentiginous melanomas, and one lentigo maligna (Hutchinson’s freckle) melanoma; (2) 21 subcutaneous melanomas metastases including two in fibrofatty tissue and one in skeletal muscle; (3) 17 lymph node metastases; (4) 10 dysplastic naevi; and (5) 10 compound naevi. Dysplastic naevi were diagnosed on the basis of histological criteria: (1) somewhat symmetrical, (2) uniform slight elongation of rete in the lentiginous compartment with bridging nests or anastomosing rete, (3) cosinophilic fibroplasia or lamellar fibroplasia present, (4) moderate cytological atypia, and (5) absence of mitoses in the dermis. The 42 primary cutaneous melanomas were from patients treated at the Sydney Melanoma Unit over the period December 2000 to March 2002. Haematoxylin and eosin stained sections of all cutaneous melanomas were from patients treated at the Sydney Melanoma Unit. The Breslow thickness of the primary melanoma was measured and also according to radial and vertical growth phase, mitosis, Clark level, and cytological factors was not seen.

**Table 1**

<table>
<thead>
<tr>
<th>Melanocytic lesions</th>
<th>N</th>
<th>Median age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound naevus</td>
<td>10</td>
<td>36.5</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>Dysplastic naevi</td>
<td>10</td>
<td>36.5</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Melanoma &lt; 1.0 mm</td>
<td>18</td>
<td>67.5</td>
<td>7</td>
<td>11</td>
</tr>
<tr>
<td>Melanoma &gt; 1.0 mm</td>
<td>24</td>
<td>69.5</td>
<td>21</td>
<td>3</td>
</tr>
<tr>
<td>Subcutaneous metastasis</td>
<td>21</td>
<td>74</td>
<td>12</td>
<td>9</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td>17</td>
<td>60</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>62</td>
<td>38</td>
<td>38</td>
</tr>
</tbody>
</table>

**Statistical analysis**

Statistical analysis was performed with Microsoft Excel 2000 software and “JMP Statistics Made VisualTM” software (SAS Institute Inc, Trumbull, Connecticut, USA). The correlation between ERK1/2 and p-ERK staining and groups of naevi and melanoma was performed using the one way ANOVA two tailed t test. Comparisons for each pair were made using the Student’s t test and comparisons for all pairs using the Tukey-Kramer HSD method. The comparisons for p-ERK expression in nodular melanoma, desmoplastic melanoma, superficial spreading melanoma, dysplastic naevi, and compound naevi used the one way ANOVA two tailed t test, the Student’s t test for each pair, and the Tukey-Kramer HSD multiple comparison tests; acral lentiginous melanoma, in situ melanoma, and lentigo maligna melanoma were excluded from this comparison because of the small numbers of these cases studied. The correlation between p-ERK expression in each primary melanoma and tumour Breslow thickness and mitotic rate was assessed using regression analysis.

**RESULTS**

Table 1 shows the types of tumours and their corresponding patient demographics. The patients’ ages ranged from 16 to 93 years and the median age was 66 years. Thirty eight (38%) were female and sixty two (62%) were male. For the 42 cases of primary melanoma, ages ranged from 23 to 84 years and the median age was 69 years. Fourteen were female and twenty eight were male. The Breslow thickness of the tumours ranged from 0.1 to 16 mm. There were 24 cases of primary melanoma > 1 mm and 18 cases of primary melanoma ≤ 1 mm or 28 vertical growth phase and 14 radial growth phase cases.

As shown in fig 1, ERK1/2 was expressed to varying degrees in all cases. The percentages of positive cells ranged from 40% to 100%. The mean percentages of positive cells in dysplastic naevi, thin melanomas, and thick melanomas were 99.6%, 98.9%, and 84.1%, respectively (table 2). ERK1/2 appeared to be expressed in both the cytoplasm and nucleus of melanocytic cells. The distribution of staining was diffuse rather than focal and ranged in intensity from 1 to 3 (fig 1A–F). Only low amounts of ERK1/2 were detected in melanocytes of normal skin (fig 1G). In seven of 24 cases of thick

---

Zhuang, Lee, Scolyer, et al
melanoma, ERK1/2 expression was more intense at the deep margin of the tumour.

p-ERK was expressed in 95 melanomas and naevi, with the percentage of positively staining cells ranging from 5% to 100%. The mean percentages of cells positive for p-ERK in compound naevi, dysplastic naevi, thin melanomas, thick melanomas, and subcutaneous melanoma metastases were 32.4%, 54.5%, 64.6%, 77.1%, and 76.3%, respectively. These differences were highly significant using the one way ANOVA two tailed t test (p < 0.0005; table 2). The mean percentage of cells in thick melanomas with activated p-ERK was higher than in dysplastic naevi (p < 0.01), compound naevi (p < 0.0001), and lymph node metastases (p < 0.005) using the Student’s t test, and was higher than in compound naevi (p < 0.0001) and lymph node metastases (p < 0.005) (fig 2) using the Tukey-Kramer method for multiple comparisons.

In patients with metastatic melanoma, p-ERK was expressed in a higher percentage of cells in subcutaneous metastases compared with lymph node metastases (p < 0.005) and compound naevi (p < 0.001) (fig 2). The distribution of positive cells was heterogeneous. The staining intensity was weaker in benign lesions than in malignant lesions. Most naevi had a staining intensity of 1 (fig 3A–F). p-ERK was not detected in melanocytes of normal skin (fig 3G). p-ERK expression in thick melanomas was more intense towards the tumour margins, particularly the deep margin.

The IRS was estimated in the radial and vertical growth phases of primary melanoma (table 3). The correlation between p-ERK expression and histological subtypes of melanoma was also assessed. There was a higher percentage of cells positive for p-ERK in nodular melanomas than in compound naevi (p < 0.0005), and a trend towards a higher percentage in nodular melanomas compared with superficial spreading melanomas (p = 0.27) (fig 4). The relation of p-ERK to thickness or the dermal mitotic rate in the primary melanoma was also assessed. As shown in fig 5 there was a weak but not significant trend for p-ERK to be higher in thick melanoma (p = 0.17) and there was also a trend towards

<p>| Table 2: ERK1/2 and p-ERK in the different types of melanocytic lesions |
|---------------------------------|----------------|----------------|----------------|----------------|</p>
<table>
<thead>
<tr>
<th>Melanocytic lesion</th>
<th>Total no. in each group</th>
<th>ERK1/2</th>
<th>p-ERK</th>
<th>p-ERK %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound naevus</td>
<td>10</td>
<td>87.9</td>
<td>18.1</td>
<td>7/10</td>
</tr>
<tr>
<td>Dysplastic naevus</td>
<td>10</td>
<td>99.1</td>
<td>19.4</td>
<td>10/10</td>
</tr>
<tr>
<td>Melanoma &lt;1.0 mm</td>
<td>18</td>
<td>98.9</td>
<td>24.5</td>
<td>18/18</td>
</tr>
<tr>
<td>Melanoma &gt;1.0 mm</td>
<td>24</td>
<td>84.1</td>
<td>17.2</td>
<td>24/24</td>
</tr>
<tr>
<td>Radial growth phase</td>
<td>14</td>
<td>98.7</td>
<td>24.7</td>
<td>14/14</td>
</tr>
<tr>
<td>Vertical growth phase</td>
<td>28</td>
<td>86.3</td>
<td>21.6</td>
<td>28/28</td>
</tr>
<tr>
<td>Subcutaneous metastasis</td>
<td>21</td>
<td>93.1</td>
<td>23.7</td>
<td>21/21</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td>17</td>
<td>88.7</td>
<td>17.1</td>
<td>15/17</td>
</tr>
</tbody>
</table>

Subcutaneous metastases included two cases in fibrous fat tissue and one case in skeletal muscle. Thick, melanoma >1.0 mm; thin, melanoma ≤1.0 mm; %, mean percentage.

*Student’s t test; †Tukey-Kramer test for multiple comparisons.

CN, compound naevus; DN, dysplastic naevus; ERK, extracellular signal regulated kinase; IRS, immunoreactive score; LN, lymph node; p-ERK, activated extracellular signal regulated kinase; SC, subcutaneous.
increased p-ERK expression with increased dermal mitotic rate, although this was not significant (p = 0.47).

**DFS and OS**

During follow up of the 42 patients with primary cutaneous melanoma (median follow up 43.5 months), 15 patients developed recurrent melanoma. Among those, five had locoregional recurrences, two had distant metastases, and eight patients had both. Nine patients died with melanoma. No patients with melanoma ≤ 1 mm thickness had a recurrence or died (fig 6A). In patients with melanoma > 1 mm thickness there were trends for differences in DFS (χ² = 0.27, p = 0.6) and OS (χ² = 1.47, p = 0.23) in patients with percentages of p-ERK positive cells above and below the median % value (80%) (fig 6B). There was no relation between IRS score and DFS or OS except when comparisons were made between survival in those with IRS scores ≤ 20 (20 patients) or > 20 (three patients) (DFS: χ² = 6.98, p = 0.008; OS: χ² = 9.95, p = 0.002). There was no significant difference between OS in patients with IRS scores above or below the median IRS of 15 (p = 0.8). There were also no differences in DFS or OS at different cutoff values for percentage of p-ERK positive cells (> 50%/≤ 50%, > 60%/≤ 60%, and > 70%/≤ 70%; data not shown).

**Figure 2** Mean percentage of cells positive for activated extracellular signal regulated kinase (p-ERK) in different types of melanocytic lesions. CN, compound naevus; DN, dysplastic naevus melanoma; LNMM, lymph node metastatic melanoma; M, melanoma; SMM, subcutaneous metastatic melanoma; thick, > 1.0 mm; thin, ≤ 1.0 mm. The Y bar indicates one standard error. *CN v thick M, p < 0.0001 (Tukey-Kramer); CN v SMM, p < 0.001 (Tukey-Kramer); **thick M v LNMM, p < 0.005.

**Figure 3** Activated extracellular signal regulated kinase (p-ERK) expression in different types of primary and secondary melanocytic tumours. (A) Compound naevus: (1) p-ERK(+); positive cells, 95%; immunoreactive score (IRS), 9.5; original magnification, ×100; (2) p-ERK(−); original magnification, ×200. (B) Dysplastic naevus; positive cells, 50%; IRS, 5; original magnification, ×200. (C) Melanoma ≤ 1.0 mm; positive cells, 97%; IRS, 19.4; original magnification, ×200. (D) Melanoma > 1.0 mm; positive cells, 98%; IRS, 24.5; original magnification, ×100. (E) Desmoplastic melanoma; positive cells, 70%; IRS, 7; original magnification, ×200. (F) Metastatic melanoma: (1) subcutaneous metastasis; positive cells, 98%; IRS, 19.6; original magnification, ×200; (2) lymph node metastasis, p-ERK(+); positive cells, 90%; IRS, 18; original magnification, ×200; (3) lymph node metastasis, p-ERK(−); original magnification, ×200. (G) Normal skin melanocytes; p-ERK(−); original magnification, ×400.
**DISCUSSION**

In previous studies we found that activation of the ERK1/2 pathway inhibited apoptosis in a wide range of melanoma lines. Activation of this pathway is also known to be involved in regulation of the cell cycle through the retinoblastoma protein pathway.\(^1\) In view of these findings, we and others have hypothesised that activation of this pathway may be important in the development and progression of melanoma.\(^{2,3}\) Our present study sought to obtain more evidence for this hypothesis by studies on sections of formalin fixed tissue that could not be influenced by in vitro manipulation and tissue culture.

The results showed that activated ERK1/2 (p-ERK) was found more frequently in primary melanoma than in naevi and that within naevi, p-ERK expression was higher in dysplastic naevi than in compound naevi. Within melanoma, nodular melanoma had higher expression than superficial spreading forms of melanoma. Therefore, increased expression of p-ERK correlated in general with the malignant potential of the lesions, ranging from compound naevi having low potential followed by dysplastic naevi, superficial spreading melanoma, and nodular melanoma. Further support for a relation with progression of melanoma was the finding that p-ERK was increased at the deeper margins of primary melanoma where the tumour was expanding and invading into the dermis.

"Increased expression of p-ERK correlated in general with the malignant potential of the lesions, ranging from compound naevi having low potential followed by dysplastic naevi, superficial spreading melanoma, and nodular melanoma."

We examined whether p-ERK expression was related to other known prognostic features such as depth and mitotic rate of the primary tumour. There was a non-significant trend for the depth of melanoma to be associated with p-ERK expression, but there was no clear association with the mitotic rate. These results may indicate that other signalling pathways, such as the protein kinase B (Akt) pathway,\(^{19}\) are also involved, and that these impact on the mitotic rate, which was used as a measure of cell division in our study.

The higher percentage of cells positive for p-ERK in nodular melanoma compared with benign naevi and superficial spreading melanoma is of interest because activating mutations of N-ras (upstream of ERK1/2) have been reported to be more frequent in nodular melanoma and lentigo maligna melanomas.\(^{27,28}\) Unfortunately, we were not able to assess N-ras mutations in our samples. The expression of p-ERK in subcutaneous metastases was similar to that seen in thick melanoma, but an unexpected finding was the significantly lower percentage of tumour cells positive for p-ERK in 17 lymph node metastases (48.5%) compared with metastases in subcutaneous sites (76.3%) (Student’s t test, \(p < 0.005\)). An explanation for these findings is not readily apparent. Mutations of N-ras and B-RAF were reported to be more frequent in cutaneous or soft tissue melanoma metastases,\(^{29}\) and this may in part account for the differences. Alternatively, it is possible that the microenvironment in lymph nodes inhibited activation of the ERK1/2 pathway. Further study of metastases at these sites is required to answer this question.

In addition to examining the correlation between p-ERK expression in melanoma and clinicopathological features, we...
tested its association with DFS and OS in patients with primary melanoma. There were no recurrences or deaths in patients with thin melanoma (< 1 mm), but in patients with melanoma > 1 mm thickness, those with p-ERK % values above the median tended to have a lower OS than those with values below the median (p = 0.23). These findings provide further support for the view that activation of ERK1/2 is related to the progression of melanoma. However, the patient numbers in our study were small and did not warrant multivariate analysis of the data.

The mechanisms underlying activation of the ERK1/2 kinases are not clear. ERK1/2 kinases may be activated by ligand interaction with tyrosine kinase receptors via RAS kinase, RAF kinase, and MAPK kinase or by crosstalk with the protein kinase C pathway. Therefore, it is possible that paracrine or autocrine growth factors, such as fibroblast growth factor or chemokines, are responsible for activation of the pathway. Activating mutations of B-RAF upstream of ERK1/2 are relatively common in melanoma and naevi. If this was the only factor involved, p-ERK would be expected to be expressed equally in naevi and melanomas, which was not the case in our study or in other studies. It has been found that transfection of mutated B-RAF into melanocytes results in activation of ERK1/2 but B-RAF is not required for signalling by mutated N-ras. N-ras mutations are believed to be infrequent in melanoma (occurring in approximately 11%). In addition, studies by others have shown that divergent pathways may exist upstream of ERK1/2. Interestingly, high amounts of p-ERK are seen in Spitz naevi, but these lesions usually have a low mitotic rate, possibly because of high concentrations of p16 cell cycle inhibitory proteins.

Irrespective of the cause of ERK activation in melanoma, our data support the concept that inhibition of this cell signalling pathway might be useful in the treatment of melanoma. Our previous studies showing the importance of ERK1/2 in the resistance of melanoma to apoptosis also indicate that this pathway may be an important target in the treatment of melanoma with apoptosis inducing agents. This has been supported by the promising results of studies in preclinical models with the MAPK kinase inhibitor CI1040 and phase I/II studies in patients treated with Carboplatin and Paclitaxel together with the Bayer BRAF inhibitor, BAY 43-9006. Our present study suggests that approximately 90% of patients with metastatic disease have some degree of activation of this pathway and hence may benefit from this treatment approach.

ACKNOWLEDGEMENTS
We thank the staff of the Department of Anatomical Pathology, Royal Prince Alfred Hospital, especially S Davies and D Maguire, for their assistance with immunohistochemistry; the staff of the Oncology and Immunology Unit of the Newcastle Mater Misericordiae Hospital for their assistance and comments; and M Colman from the Sydney Melanoma Unit Database for follow up information.

Authors’ affiliations
L Zhuang, C S Lee, R A Scolyer, S W McCarthy, A A Palmer, Department of Anatomical Pathology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
J F Thompson, L P Bron, Sydney Melanoma Unit and the Melanoma and Skin Cancer Research Institute, Royal Prince Alfred Hospital
X D Zhang, P Hersey, Oncology and Immunology Unit, Newcastle Mater Misericordiae Hospital, Newcastle, NSW 2300, Australia

REFERENCES
ERK and p-ERK in melanoma